MEDIPOST Completes Phase 2a Clinical Trial of NEUROSTEM for Alzheimer’s Disease2020/07/07STEM CELL THERAPEUTIC
MEDIPOST Completes Phase 2a Clinical Trial of NEUROSTEM for Alzheimer’s Disease2020/01/06STEM CELL THERAPEUTIC
MEDIPOST’s Alzheimer’s Disease Drug Approved by FDA for Clinical Trials2018/02/05STEM CELL THERAPEUTIC
MEDIPOST Obtains Patent for Core Alzheimer’s Disease Treatment Technology in Six European Countries2017/10/25STEM CELL THERAPEUTIC
MEDIPOST Obtains Patent in Canada for its Stem Cell-based Alzheimer’s Disease Treatment Composition2017/06/28STEM CELL THERAPEUTIC
MEDIPOST Obtains Patent in UK for its Alzheimer’s Disease Treatment Technique that Uses Stem Cells2017/05/17STEM CELL THERAPEUTIC
MEDIPOST Obtains Patent in US for its Alzheimer’s Disease Treatment Drug2016/06/08STEM CELL THERAPEUTIC
MEDIPOST Obtains Patent in China for its Alzheimer’s Disease Treatment Substance2016/04/06STEM CELL THERAPEUTIC
MEDIPOST Obtains Stem Cell Therapy Patent in Japan for Treating Alzheimer’s Disease2016/01/13STEM CELL THERAPEUTIC
Core dementia treatment technology patented at 6 European countries, concurrently2015/07/30STEM CELL THERAPEUTIC
Successful administration of stem cell dementia treatment drug ‘NEUROSTEM’2014/04/28STEM CELL THERAPEUTIC
MEDIPOST Submits Application for Product Authorization Amendment to Add Ankle Indications for CARTISTEM®2023/12/27
MEDIPOST Selected for a Government-Supported R&D Project Worth KRW 13 billion, to be Used for Global Market Expansion Including the U.S.2023/10/04
MEDIPOST’s CARTISEM®, Umbilical Cord Blood-derived Stem Cell Transplant Surgery Clinical Study Results Published in SCI-Level Journal2023/05/02
MEDIPOST Treats First Subject with CARTISTEM® in Japan Phase 3 Clinical Trial, Accelerating Clinical Development efforts in Japan2023/01/16
MEDIPOST Enhances its Partnership with Canada’s OmniaBio in Collaboration for the CMDO Business of OmniaBio’s All-Around Cell and Gene Therapy.2022/12/01